Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
- PMID: 3373218
- DOI: 10.1111/j.1471-4159.1988.tb02497.x
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
Abstract
The main objective of the present study was to determine whether cholinergic markers (choline acetyltransferase activity and nicotinic and muscarinic receptors) are altered in Alzheimer's disease. Choline acetyltransferase activity in Alzheimer's brains was markedly reduced in various cortical areas, in the hippocampus, and in the nucleus basalis of Meynert. The maximal density of nicotinic sites, measured using the novel nicotinic radioligand N-[3H]methylcarbamylcholine, was decreased in cortical areas and hippocampus but not in subcortical regions. M1 muscarinic cholinergic receptor sites were assessed using [3H]pirenzepine as a selective ligand; [3H]pirenzepine binding parameters were not altered in most cortical and subcortical structures, although the density of sites was modestly increased in the hippocampus and striatum. Finally, M2-like muscarinic sites were studied using [3H]-acetylcholine, under muscarinic conditions. In contrast to M1 muscarinic sites, the maximal density of M2-like muscarinic sites was markedly reduced in all cortical areas and hippocampus but was not altered in subcortical structures. These findings reveal an apparently selective alteration in the densities of putative nicotinic and muscarinic M2, but not M1, receptor sites in cortical areas and in the hippocampus in Alzheimer's disease.
Similar articles
-
Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites.J Neurosci. 1990 Sep;10(9):3069-78. doi: 10.1523/JNEUROSCI.10-09-03069.1990. J Neurosci. 1990. PMID: 2398371 Free PMC article.
-
Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases.J Neurochem. 1992 Feb;58(2):529-41. doi: 10.1111/j.1471-4159.1992.tb09752.x. J Neurochem. 1992. PMID: 1729398
-
Effect of chronic nicotine treatment on nicotinic autoreceptor function and N-[3H]methylcarbamylcholine binding sites in the rat brain.J Neurochem. 1989 Feb;52(2):483-91. doi: 10.1111/j.1471-4159.1989.tb09146.x. J Neurochem. 1989. PMID: 2911027
-
Dysfunction of the brain cholinergic system during aging and after lesions of the nucleus basalis of Meynert.J Neural Transm Suppl. 1994;44:189-94. doi: 10.1007/978-3-7091-9350-1_14. J Neural Transm Suppl. 1994. PMID: 7897390 Review.
-
Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease.Trends Pharmacol Sci. 1989 Dec;Suppl:80-4. Trends Pharmacol Sci. 1989. PMID: 2694529 Review.
Cited by
-
Cholinomimetic activities of minaprine.Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):411-8. doi: 10.1007/BF00167042. Naunyn Schmiedebergs Arch Pharmacol. 1989. PMID: 2586634
-
Increased CSF HVA response to arecoline challenge in Alzheimer's disease.J Neural Transm Gen Sect. 1992;90(1):53-65. doi: 10.1007/BF01250518. J Neural Transm Gen Sect. 1992. PMID: 1281646
-
Mapping of human and macaque sensorimotor areas by integrating architectonic, transmitter receptor, MRI and PET data.J Anat. 1995 Dec;187 ( Pt 3)(Pt 3):515-37. J Anat. 1995. PMID: 8586553 Free PMC article.
-
Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.Expert Rev Med Devices. 2012 Jan;9(1):71-83. doi: 10.1586/erd.11.64. Expert Rev Med Devices. 2012. PMID: 22145842 Free PMC article. Review.
-
L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.Br J Pharmacol. 1992 Oct;107(2):494-501. doi: 10.1111/j.1476-5381.1992.tb12773.x. Br J Pharmacol. 1992. PMID: 1422595 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical